Carregant...
Novel Oral Anticoagulants in Atrial Fibrillation: Update on Apixaban
Almost 800,000 new or recurrent strokes occur every year. Atrial fibrillation, the most common cardiac arrhythmia, is a major risk factor for stroke, accounting for 15-20% of ischemic strokes. Apixaban is a direct inhibitor of Factor Xa that was approved in December 2012 by the US Food and Drug Admi...
Guardat en:
| Publicat a: | Curr Cardiol Rev |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Bentham Science Publishers
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5324317/ https://ncbi.nlm.nih.gov/pubmed/27450450 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2174/1573403X12666160720092024 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|